Clinical Trial Update: Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating MT1013 for secondary hyperparathyroidism in patients with chronic kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• MT1013

Snippet

Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Status: RECRUITING